Now sequencing · CLIA-certified · CAP-accredited

Read the genome.
Rewrite the outcome.

Codon pairs 30x whole-genome sequencing with a precision-therapeutics engine — turning three billion base pairs into a clinical plan for longer, healthier lives.

30×
Mean WGS depth
72h
Median turnaround
99.9%
Base-call accuracy
01By the numbers
18.4k
Genomes sequenced
Across research and clinical programs since 2019.
4.7M
Variants curated
Annotated against ClinVar, gnomAD and internal cohorts.
11
Therapeutic programs
From preclinical discovery through Phase III.
96%
Clinician retention
Ordering providers active twelve months on.
02The platform

One sample. The whole genome, end to end.

A single blood or saliva draw moves through extraction, library prep, sequencing and interpretation without ever leaving our accredited lab — no third-party handoffs, no black boxes.

/01

Sample & library prep

Automated DNA extraction and PCR-free library construction on the Codon liquid-handling line, standardized for reproducibility.

/02

Short + long-read sequencing

Hybrid Illumina and Oxford Nanopore chemistry resolves structural variants and phasing that short reads alone miss.

/03

Codon interpretation engine

Alignment, variant calling and ACMG classification in a validated bioinformatics pipeline with per-run QC gates.

/04

Clinical report & counseling

Board-certified geneticists sign out every report; genetic counseling is included with each clinical result.

03Clinical panels

Focused reads for the questions that matter now.

CDN-COREWGS

Codon Core WGS

The complete 30× whole genome — the foundation every other panel reads against, re-analyzed as knowledge grows.

3.2B
Base pairs
72h
Turnaround
ONC-427ONCOLOGY

Onco-Guard 427

Hereditary cancer risk across 427 genes including BRCA1/2, Lynch and TP53, with actionable surveillance guidance.

427
Genes
99.8%
Sensitivity
CDX-CVCARDIO

CardioSeq

Inherited cardiomyopathy, arrhythmia and aortopathy genes, phased to distinguish variants in cis from trans.

216
Genes
5d
Turnaround
NRX-RARENEURO

NeuroRare

Trio analysis for undiagnosed neurodevelopmental disease, combining WGS with repeat-expansion detection.

1.8k
Genes
41%
Diagnostic yield
PGX-PRDPHARMA

PharmacoPredict

CPIC-guided pharmacogenomics across 23 star-allele genes, mapping drug response before the first prescription.

23
Gene / drug pairs
48h
Turnaround
LNG-AGELONGEVITY

Longevity Index

Polygenic scores and epigenetic-age readouts for metabolic, cardiovascular and cognitive trajectories over time.

14
Risk models
Annual
Re-analysis
04Therapeutic pipeline

From variant to therapy.

Programs advancing genetically defined medicines — each seeded by a signal first seen in our sequencing cohort.

Program
Preclinical
Phase I
Phase II
Phase III
CDN-101ATTR cardiomyopathy · siRNA
Phase III
CDN-204Familial hypercholesterolemia · base edit
Phase II
CDN-315Early-onset Parkinson (GBA) · AAV
Phase I
CDN-338Hereditary ATTR polyneuropathy · siRNA
Phase I
CDN-402Metabolic aging (mTOR axis) · small molecule
Preclinical
05Selected publications

Peer-reviewed, reproducible, open where we can be.

06Trust & compliance

Clinical-grade by default.

CLIA / CAP

Accredited laboratory

Codon Labs holds CLIA certification and CAP accreditation; every clinical assay is validated and monitored under a documented quality system.

HIPAA

Protected by design

Genomic and health data are encrypted in transit and at rest under HIPAA safeguards, with role-based access and full audit trails.

Consent

You own your data

Research use is opt-in and revocable. Participants control secondary use and can withdraw and request deletion at any time.

GA4GH

Interoperable standards

Reports and data exchange follow GA4GH and HL7 FHIR genomics standards so results move cleanly into the EHR.

Request access

Sequence once. Act for a lifetime.

Partner with Codon as a clinician, health system or research program. We will walk you through onboarding, ordering and reporting.